# Zhimeng Biopharma has completed the patients enrollment of its investigational drug, CB03-154, in the pivotal Phase 2/3 ALS clinical trial.

- Source: PR Newswire M&A
- Published: 2026-10-31T05:00:00+00:00
- Category: Business
- Original: https://www.prnewswire.com/news-releases/zhimeng-biopharma-has-completed-the-patients-enrollment-of-its-investigational-drug-cb03-154-in-the-pivotal-phase-23-als-clinical-trial-302924801.html
- Canonical: https://groundlevelnews.com/story/zhimeng-biopharma-has-completed-the-patients-enrollment-of-its-investi-c44a0b/

SHANGHAI, Oct. 31, 2026 /PRNewswire/ -- Shanghai Zhimeng Biopharma, Inc. ( "Zhimeng Biopharma") announced today that its independently developed next-generation potassium channel opener, CB03-154, intended for the treatment of amyotrophic lateral sclerosis (ALS), has successfully...

_Ground Level News shows a short summary only; the full article and all rights belong to PR Newswire M&A._